Dosing and uses of Vigamox (moxifloxacin ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.5%
Bacterial Conjunctivitis
Moxeza: 1 drop instilled into affected eye(s) q12hr for 1 week
Vigamox: 1 drop instilled into affected eye(s) q8hr for 1 week
Pediatric dosage forms and strengths
ophthalmic solution
- 0.5%
Bacterial Conjunctivitis
Moxeza
- <4 months: Safety and efficacy not established
- >4 months: 1 drop instilled into affected eye(s) q12hr
Vigamox
- <1 year: Safety and efficacy not established
- >1 year: 1 drop instilled into affected eye(s) q8hr for 1 week
Vigamox (moxifloxacin ophthalmic) adverse (side) effects
1-10%
Conjunctivitis
Dry eye
Fever
Increased cough
Infection
Ocular discomfort
Ocular hyperemia
Ocular pain
Ocular pruritus
Otitis media
Pharyngitis
Rash
Rhinitis
Subconjunctival hemorrhage
Tearing
Warnings
Contraindications
Hypersensitivity to quinolones or other components of formulation
Cautions
May result in overgrowth of nonsusceptible organisms, including fungi
Some patients may require slit-lamp biomicroscopy and fluorescein staining
Pregnancy and lactation
Pregnancy category: C
Lactation: Unknown whether drug is excreted in breast milk; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Vigamox (moxifloxacin ophthalmic)
Mechanism of action
Fluoroquinolone antibiotic; bactericidal; inhibits DNA gyrase in susceptible organisms and also inhibits topoisomerase IV
Absorption
Peak plasma concentration: 2.7 ng/mL
AUC: 45 ng/hr/mL
Elimination
Half-life: 13 hr
